BNP Paribas Financial Markets Has $1.58 Million Stake in LivaNova PLC (NASDAQ:LIVN)

BNP Paribas Financial Markets grew its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,185 shares of the company's stock after purchasing an additional 6,340 shares during the period. BNP Paribas Financial Markets owned approximately 0.06% of LivaNova worth $1,583,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock worth $108,823,000 after buying an additional 265,291 shares during the period. Capital Research Global Investors boosted its holdings in shares of LivaNova by 19.1% in the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock worth $74,690,000 after buying an additional 258,730 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of LivaNova by 8.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock worth $60,710,000 after buying an additional 107,693 shares during the period. Emerald Advisers LLC boosted its holdings in shares of LivaNova by 8.2% in the fourth quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock worth $34,850,000 after buying an additional 57,035 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in shares of LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock worth $34,214,000 after buying an additional 328,313 shares during the period. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

LIVN has been the subject of several recent analyst reports. Barclays decreased their target price on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a report on Tuesday. Wall Street Zen cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, Robert W. Baird increased their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $59.29.

LivaNova Stock Down 3.0%

Shares of LivaNova stock traded down $1.30 during midday trading on Friday, reaching $41.88. 602,740 shares of the company's stock traded hands, compared to its average volume of 651,153. The company has a market cap of $2.28 billion, a price-to-earnings ratio of 99.71 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $61.94. The company's 50 day simple moving average is $38.77 and its 200 day simple moving average is $44.60.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.